Frederick, MD – Jecho Laboratories, Inc.will present three proprietary progams in poster format at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The featured innovations include:
- Development of JLF025: an optimized anti-mesothelin T-cell engager for enhanced safety and efficacy
- Persistent elimination of tumors via balanced regulation of immune signals
- Development of an anti-TF ADC with a potentially improved therapeutic index
As one of the world’s largest and most influential cancer research conferences, the 2025 AACR Annual Meeting will be held April 25–30, 2025, in Chicago.
“These presentations represent a key milestone in Jecho’s growth,” said by the Chief Executive Officer of Jecho Laboratories. “We are proud to demonstrate our evolution from a fast follower to a global innovator in drug development. Our team is focused on delivering differentiated therapies that address unmet needs through scientific rigor, targeted design, and a commitment to patient impact.”
Details on presentation are below:
- Development of an anti-TF ADC with a potentially improved therapeutic index
• Abstract Presentation Number: 348
• Poster Section: 16
• Session Time: April 27, 2025, 2:00 PM – 5:00 PM (U.S. Central Time)
• AACR Link: https://www.abstractsonline.com/pp8/#!/20273/presentation/3205
- Persistent elimination of tumors via balanced regulation of immune signals
• Abstract Presentation Number: 2230
• Poster Section: 38
• Session Time: April 28, 2025, 9:00 AM – 12:00 PM (U.S. Central Time)
• AACR Link: https://www.abstractsonline.com/pp8/#!/20273/presentation/8429
- Development of JLF025, an anti-mesothelin T cell engager optimized for efficacy and safety
• Abstract Presentation Number: 6021
• Poster Section: 35
• Session Time: April 29, 2025, 2:00 PM – 5:00 PM (U.S. Central Time)
• AACR Link: https://www.abstractsonline.com/pp8/#!/20273/presentation/1929